NCT06970080View on ClinicalTrials.gov

Therapeutic Relevance of Abnormal Airway Morphology in Asthma

PHASE4RecruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Asthma
Interventions
DRUG

Inhaled corticosteroid (ICS)

In Phase I, participants will receive additional same dose of extra-fine particle ICS (i.e., their ICS would be doubled) for 12-weeks.

DRUG

Oral Corticosteroid (OCS)

In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.

Trial Locations (2)

L8N4A6

RECRUITING

St. Joseph's Healthcare Hamilton, Hamilton

N6A 3K7

NOT_YET_RECRUITING

Western University, London

All Listed Sponsors
lead

McMaster University

OTHER